Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/06—Antibacterial agents for tuberculosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/08—Antibacterial agents for leprosy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
  • A61P33/06—Antimalarials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to new phenyl- and pyridyl-piperidines, the pharmaceutical compositions containing them and a process for their preparation.
• FR 2477542 describes piperidines and piperazines substituted by carbostyrils, having mainly antihistamine activity
• TNF-alpha is a cytokine which has recently aroused interest as a mediator of immunity, inflammation, cell proliferation, fibrosis etc. This mediator is abundantly present in inflamed synovial tissue and exerts an important role in the pathogenesis of autoimmunity (Annu Rep Med Chem, 1997, 32 241-250)
• X represents N or CH
• Ri represents a hydrogen or halogen atom or a group
• R 2 and R 3 independently represent a hydrogen atom or a methyl group, is 0 or 1, represents a condensed heterocyclic group of formula (w)
• nucleus either a 5 atom nucleus, aromatic or saturated, containing a nitrogen, oxygen or sulfur atom, the nucleus being able to be substituted by one or two (C ⁇ -C) alkyl groups; as well as their N-oxides and their salts or solvates,
• halogen denotes a chosen atom
• Preferred compounds are those where n is zero.
• Ri is a group CF 3 .
• Other preferred compounds are those where Ri is a fluorine atom.
• Particularly preferred compounds are the compounds of formula (I) where A is chosen from quinoline, pisoquinoline, quinoxaline, cinnoline and phthalazine, optionally substituted by one or two (C ⁇ -C) alkyl groups.
• Particularly preferred compounds are the compounds of formula (I) where -, A is chosen from indole, benzothiophene and benzofuran.
• the subject of the invention is the compounds of formula (I) where A is a group of formula (a) or (b):
• R4 represents a hydrogen or halogen atom, a (C ⁇ -C 4 ) alkyl group, a CF 3 group, an amino group, mono (C ⁇ - C 4 ) alkylamino, di (C ⁇ -C) alkylamino;
• R 5 represents a hydrogen or halogen atom, a group
• R ⁇ represents a hydrogen atom, a (Cj-C 4 ) alkyl group or a (C ⁇ -C 4 ) alkoxy group; as well as their salts or solvates.
• Particularly preferred compounds are the compounds of formula (I) where A is a group of formula (a) or (b) and Rt, R 5 , and R 5 are hydrogen atoms.
• the compounds of formula (I) can exist as N-oxide derivatives.
• the compounds of formula (I) can in particular carry the N-oxide group on piperidine or else on the nitrogen groups (w), (a) and (b), or all Nitrogen present can be simultaneously oxidized.
• the salts of the compounds of formula (I) according to the present invention also include the addition salts with pharmaceutically acceptable inorganic or organic acids such as the hydrochloride, the hydrobromide, the sulfate, the hydrogen sulfate, the dihydrogen phosphate, the citrate, maleate, tartrate, fumarate, gluconate, methanesulfonate, 2-naphthalenesulfonate, etc., than addition salts which allow proper separation or crystallization of the compounds of formula (I), such as picrate, oxalate or addition salts with optically active acids, for example example camphosulfonic acids and substituted mandelic or mandelic acids
• the compounds of formula (I) can be prepared by a condensation / reduction reaction starting from a compound of formula (II)
• the condensation / reduction reaction is carried out by mixing the starting compounds (II) and (III) in an organic solvent such as an alcohol, for example methanol, in an acid medium, in the presence of a reducing agent.
• a reducing agent such as sodium cyano-borohydride, according to conventional methods
• the compounds of formula (I) can be prepared by a process which provides (a) for reacting the compound of formula (II) 5
• step (a) can be conveniently carried out in an organic solvent at a temperature between -10 ° C and the reflux temperature of the reaction mixture.
• BOP tri (dimethylamino) benzotriazol-1-yloxyphosphonium hexafluorophosphate
• anhydride a mixed anhydride
• an active ester or an acid halide preferably bromide.
• p-nitrophenyl ester is particularly preferred, but methoxyphenyl, trityl, benzhydryl esters and the like are also suitable.
• a halogenated solvent such as methylene chloride, dichloroethane, 1,1,1-trichloroethane, chloroform and the like, but also other organic solvents compatible with the reagents used, are preferably used.
• dioxane, tetrahydrofuran or a hydrocarbon such as hexane, or dimethylformamide (DMF) can also be used.
• the reaction can be suitably carried out in the presence of a proton acceptor, for example an alkali carbonate or a tertiary amine such as triethylamine (TE A).
• a proton acceptor for example an alkali carbonate or a tertiary amine such as triethylamine (TE A).
• step (b) can be suitably carried out by suitable reducing agents such as borane complexes, for example borane dimethylsulfide ([CH 3 ] 2 S-BH 3 ), aluminum hydrides or a complex lithium and aluminum hydride in an inert organic solvent at a temperature between 0 ° C. and the reflux temperature of the reaction mixture, according to the usual techniques.
• suitable reducing agents such as borane complexes, for example borane dimethylsulfide ([CH 3 ] 2 S-BH 3 ), aluminum hydrides or a complex lithium and aluminum hydride in an inert organic solvent at a temperature between 0 ° C. and the reflux temperature of the reaction mixture, according to the usual techniques.
• suitable reducing agents such as borane complexes, for example borane dimethylsulfide ([CH 3 ] 2 S-BH 3 ), aluminum hydrides or a complex lithium and aluminum hydride in an inert organic solvent at a temperature between 0 ° C. and the
• the operation is carried out with borane dimethylsulfide used in excess relative to the starting compound (III), at the reflux temperature optionally under an inert atmosphere.
• the reduction is normally finished after a few hours.
• step (b) above can also cause the reduction of said ring
• the desired compound is isolated according to conventional techniques in the form of a free base or of a salt thereof.
• the free base can be transformed into one of its salts by simple salification in an organic solvent such as an alcohol, preferably ethanol or isopropanol, an ether such as 1,2-dimethoxyethane, ethyl acetate , acetone or a hydrocarbon such as hexane.
• the compound of formula (I) obtained is isolated according to the usual techniques and optionally transformed into one of its salts or solvates or into its N-oxide derivatives.
• the compounds of formula (III) can for example be prepared by heating the trifluoromethylsulfonyl derivative (in other words “triflate”) of the compound of formula A-OH with N, N-dialkylethanolamine vinyl ether in the presence of a catalyst of palladium and a strong base such as for example triethylamine and reacting the intermediate thus obtained with concentrated sulfuric acid, according to the usual procedures. Examples of such a process are reported in the experimental part.
• the aldehydes of formula (III) can be prepared by reduction of the acid correspondents of formula (IV) according to well known methods.
• the compounds of formula (I) carrying an N-oxide group on the nitrogen atoms of groups (w), (a) and (b) can be prepared from the N-oxide derivatives of the compounds of formula (III) or (IV).
• the compounds of formula (I) carrying an N-oxide group on the nitrogen atom of piperidine can be prepared by oxidation of the corresponding compounds of formula (I).
• the compound of formula (I) as obtained by the above syntheses is subjected to an oxidation reaction according to conventional methods, for example to a reaction with m-chloro-perbenzoic acid. in a suitable solvent and isolated according to the usual techniques well known to those skilled in the art.
• the compounds of the invention have advantageous properties with respect to the inhibition of TNF- ⁇ .
• LPS lipopolysaccharide
• test products are administered orally to groups of 5 female Balb / c mice (Charles River, France) aged 7 to 8 weeks.
• the LPS is administered intravenously (10 ⁇ g / mouse).
• the blood of each animal is taken 1.5 hours after administration of the LPS.
• the samples are centrifuged, the plasma is recovered and frozen at -80 ° C.
• TNF- ⁇ is measured using commercial kits (R&D, Abingdon, UK).
• the compounds of formula (I) and its salts or solvates may well be used in the treatment of diseases linked to immune and inflammatory disorders or as analgesics.
• the compounds of formula (I) can be used to treat atherosclerosis, autoimmune diseases, diseases which cause demyelination of neurons (such as multiple sclerosis), asthma, rheumatoid arthritis, fibrotic diseases , pulmonary idiopathic fibrosis, cystic fibrosis, glumerulonephritis, rheumatoid spondylitis, osteoarthritis, gout, bone and cartilage resorption, osteoporosis, Paget's disease, multiple myeloma, uveoretinitis, septic shock , sepsis, endotoxin shock, graft versus host reaction, transplant rejection, adult respiratory distress syndrome, silicosis, asbestosis, pulmonary sarcoidosis, Crohn's
• 5 acceptable are preferably administered orally.
• the active principle in the pharmaceutical compositions of the present invention by the oral route, can be administered in unit administration forms, in admixture with conventional pharmaceutical carriers, to animals and humans for the treatment of the abovementioned conditions.
• Appropriate unit dosage forms include, for example, optionally scored tablets, capsules, powders, granules, and oral solutions or suspensions.
• the main active ingredient is mixed with a pharmaceutical vehicle such as
• a preparation in capsules is obtained by mixing the active ingredient with a diluent and pouring the mixture obtained into soft or hard capsules.
• a preparation in syrup or elixir form may contain the active ingredient together with a sweetener, preferably calorie-free, methylparaben and propylparaben as antiseptics, as well as a flavoring agent and a suitable color.
• a sweetener preferably calorie-free, methylparaben and propylparaben as antiseptics, as well as a flavoring agent and a suitable color.
• Water dispersible powders or granules may contain the active ingredient in admixture with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone, as well as with sweeteners or correctors of
• the active principle can also be formulated in the form of microcapsules, optionally with one or more carriers or additives.
• the active principle can also be in the form of an inclusion complex in the pharmaceutical compositions according to the present invention.
• the unit doses generally comprise from 0.001 to 100 mg, better still from 0.01 to 50 mg, preferably from 0.1 to 20 mg of active principle, advantageously from 0.5 to 10 mg.
• the present invention relates to a combination comprising a compound of formula (I) or one of its pharmaceutically acceptable salts or solvates, and at least one compound chosen from immunosuppressive agents, such as interferon beta -lb; adrenocorticotropic hormone; glucocorticoids such as prednisone or methylprednisolone; interleukin-1 inhibitors.
• immunosuppressive agents such as interferon beta -lb; adrenocorticotropic hormone; glucocorticoids such as prednisone or methylprednisolone; interleukin-1 inhibitors.
• the invention relates to a combination comprising a compound of formula (I), or one of its pharmaceutically acceptable salts or solvates and at least one compound chosen from roquinimex (1,2-dihydro-4-hydroxy-N , l-dimethyl-2-oxo-3-quinolinecarboxanilide), myloran (product of the company Autoimmune containing bovine myelin), antegren (human monoclonal antibody from the companies Elan / Athena Neurosciences) the recombinant beta-lb interferon .
• Other possible associations are those consisting of a compound of formula (I) or one of its pharmaceutically acceptable salts or solvates and a potassium channel blocker, such as for example fampridine (4-aminopyridine).
• the invention relates to a method of treatment of diseases linked to immune and inflammatory disorders as well as in the treatment of pain, in particular atherosclerosis, autoimmune diseases, diseases which cause the demyelination of neurons (such as multiple sclerosis), asthma, rheumatoid arthritis, fibrotic diseases, idiopathic pulmonary fibrosis, cystic fibrosis, glumerulonephritis, rheumatoid spondylitis, osteoarthritis, gout, bone and cartilage resorption , osteoporosis, Paget's disease, multiple myeloma, uveoretinitis, septic shock, sepsis, endotoxin shock, graft versus host reaction, transplant rejection, respiratory distress syndrome , silicosis, asbestosis, pulmonary sarcoidosis, Crohn's disease, ulcerative colitis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease
• 7-Hydroxy-isoquinoline trifluoromethanesulfonate is obtained in the form of an oil.
• 1.65 g of this product are mixed under argon with 27.5 ml of anhydrous dimethylformamide, 41 mg of palladium acetate, 1.65 ml of anhydrous triethylamine, 1.38 g of N, N-diethylethanolamine vinyl ether.
• the mixture is heated at 80 ° C for 36 hours. Poured into a water / ethyl acetate mixture, the two phases are separated, the organic phase is washed with water, dried and the solvent is evaporated off under reduced pressure.
• step (b) the reduction in step (b) was carried out with borane dimethylsulfide ([CH 3 ] 2 S-BH 3 ) instead of LiALHt.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Health & Medical Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Physical Education & Sports Medicine (AREA)
• Virology (AREA)
• Immunology (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Rheumatology (AREA)
• Neurosurgery (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Pulmonology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Pain & Pain Management (AREA)
• Diabetes (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Molecular Biology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Urology & Nephrology (AREA)
• Biotechnology (AREA)
• Dermatology (AREA)
• Hematology (AREA)
• Hospice & Palliative Care (AREA)
• Anesthesiology (AREA)
• Transplantation (AREA)
• Obesity (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=8862517

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (1)

Citations (1)

• 2001
  • 2001-04-20 FR FR0105361A patent/FR2823749B1/fr not_active Expired - Fee Related
• 2002
  • 2002-04-19 US US10/475,272 patent/US7326720B2/en not_active Expired - Fee Related
  • 2002-04-19 WO PCT/FR2002/001342 patent/WO2002085887A1/fr not_active Ceased
  • 2002-04-19 EP EP02727675A patent/EP1383761B1/fr not_active Expired - Lifetime
  • 2002-04-19 AT AT02727675T patent/ATE500241T1/de not_active IP Right Cessation
  • 2002-04-19 JP JP2002583414A patent/JP4324381B2/ja not_active Expired - Fee Related
  • 2002-04-19 DE DE60239324T patent/DE60239324D1/de not_active Expired - Lifetime

Patent Citations (1)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events